Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Hemophilia A & B Treatment Market Value: $6.3 Billion by 2024

By GlobalData | December 28, 2015

The market for hemophilia A and B recombinant therapies is set to experience limited growth, rising from $5.4 billion in 2014 to $6.3 billion by 2024, says research and consulting firm GlobalData.

According to the company’s latest report*, this increase represents a tepid Compound Annual Growth Rate (CAGR) of 1.52% across Argentina and the seven Major Markets (7MM) of the US, France, Italy, Spain, Germany, the UK, and Japan, a product of high treatment rates and market saturation.

Fenix Leung, DPhil, GlobalData’s Analyst covering Oncology and Hematology, explains: “Despite the availability of new, long-acting products designed to reduce injection frequency, hemophilia patients in the US and five major European countries are satisfied with established recombinant factor products.

“Overall, GlobalData expects modest uptake of long-acting Factor VIII products, while uptake of long-acting Factor IX products will be higher owing to the substantial dosing interval increase.”

However, Biogen’s Eloctate and Alprolix are competitively priced, limiting the scope of premium pricing for pipeline long-acting products. Therefore, pricing barriers should render overall market growth slow.

Drivers of hemophilia A and B recombinant therapies include the disease’s growing prevalence and the increasing use of recombinant products and prophylactic regimens.

Leung elaborates: “New patients with severe hemophilia A and B in the 7MM and Argentina, except Germany, receive prophylactic recombinant factors. As these patients are likely to stay on recombinant treatment permanently, recombinant product use should rise, driving market growth.”

In Argentina, the market is not as well-established as it is among the 7MM, leaving investment prospects more open. As such, Argentina’s hemophilia treatment market is projected to grow from $119 million in 2014 to $193 million by 2024, representing a greater CAGR of 4.9%.

Leung explains: “Most hemophilia patients in Argentina have access to factor replacement products through private insurance plans or the national social security program. However, the former are costly, and the latter only covers on-demand treatment and plasma-derived concentrates.

“Therefore, the number of patients receiving recombinant factor is low, as only 25% and 27% of hemophilia A and B patients, respectively, received recombinant replacement products in 2013.”

Despite low uptake, GlobalData expects that the Argentine market will use recombinant products more, offering opportunities to convert patients currently using plasma-derived products to using recombinant ones. This will make Argentina a lucrative region in the crowded hemophilia treatment space.

*PharmaPoint: Hemophilia A and B Recombinant Factor Replacement Therapy – Global Drug Forecast and Market Analysis to 2024

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE